Abstract
The discovery of the anaplastic lymphoma kinase (ALK) gene rearrangement as an oncogenic driver in thoracic oncology has permitted to identify a subpopulation of non-small cell lung cancer (NSCLC) that can be considered as a rare oncologic disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
